do glp 1 agonists cause muscle loss The promise and peril of GLP-1 agonists: What we (and don't) know as of August 2024 GLP-1s do not cause muscle

In 2020, Saxenda was approved for children and adolescents 12 years and older with obesity or overweight with an associated health problem, such as high blood pressure

Moreover, combination therapies have demonstrated significant advantages, such as Novo Nordisks CagriSema (semaglutide + cagrilintide), which shows superior glycemic control and weight reduction effects compared to semaglutide alone, demonstrating that combination therapy can achieve more than the sum of its parts while reducing side effects

10.2337/diabetes.50.3.609 191 WaughN.CumminsE.RoyleP.ClarC.MarienM.RichterB.et al (2010)

However, what remains to be tested in this instance is whether such export, when meant for non-regulatory or commercial reasons, enjoys the same exemption

95 There is a lack of knowledge on GLP-1RAs precise effect on neurogenesis